Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Clinical Trial

Numinus Granted Canada's Special Access Program For Magic Mushrooms To Treat Life-Threatening Conditions

Numinus Wellness Inc (OTCQB: NUMIF) has been approved to use psilocybin-assisted therapy through Health Canada’s Special Access Program (SAP), marking the first instance in which Numinus will provide this treatment outside of a clinical trial.

Benzinga

Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

Inhibrx Inc (NASDAQ:INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it. …

Benzinga

Inventiva Raises €50M Debt Financing To Fund Its Lead Program In NASH Patients

Inventiva (NASDAQ:IVA) has signed a €50 million bullet credit facility agreement with the European Investment Bank. The company plans to use the facility for its preclinical and clinical pipeline, including to help fund a portion of its Phase 3 clinical trial of lanifibranor in patients with non-alcoholic steatohepatitis (NASH). Related: Inventiva Posts Results of…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer

Athenex Inc (NASDAQ:ATNX) announced a clinical trial collaboration and supply agreement with Merck Co & Inc (NYSE:MRK). The agreement applies to the expansion phase of the Phase 1 clinical trial evaluating Athenex's oral paclitaxel combined with Merck's Keytruda (pembrolizumab) for certain NSCLC patients. The agreement will support the trial's expansion phase to investigate further the…

Benzinga

NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis

NanoViricides Inc (NYSE:NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children. The company says its top priority remains to initiate human trials of its SARS-CoV-2 drug candidate…

Benzinga

C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers

C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors.

Benzinga

Acutus Medical Completes Patient Enrolment In AcQForce Flutter IDE Trial

Acutus Medical (NASDAQ: AFIB) completed patient enrollment in the AcQForce Flutter Investigational Device Exemption (IDE) clinical trial. The trial was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

MoonLake Immunotherapeutics Begins Sonelokimab Phase 2 trial In Hidradenitis Suppurativa (HS)

MoonLake Immunotherapeutics AG (NASDAQ: MLTX) dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis suppurativa (HS).

Benzinga

Ecstasy Research Trial Completes Enrollment, Moves Closer To Approval To Treat PTSD

The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2).

Benzinga

Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs

Psychedelics policy action took center stage this week.

Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors

Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients with recurrent and/or refractory solid tumors.

Benzinga

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

Eisai Co Ltd (OTC:ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ:BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3…

Benzinga

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in CHIRON Phase 1/2a Trial for Advanced NSCLC

Achilles Therapeutics plc (NASDAQ: ACHL) announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the Company's higher-dose VELOS™ Process 2 in the ongoing Phase I/IIa CHIRON clinical trial for the treatment of advanced non-small cell lung can

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Philadelphia Inquirer

How COVID is helping us move away from white-centered clinical trials to reach more patients

PHILADELPHIA -- Rutgers researchers made a startling discovery when the pandemic curtailed routine medical visits: Going virtual to test cutting-edge therapies reached more diverse patients.

Benzinga

Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months after a low-dose (5 mcg) booster.

Benzinga

Tetra Bio-Pharma And Cannvalate Enter Into Partnership

Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN, PLENITUDE and CAUMZ clinical trials in Australia, and a subscription agreement contempl

The Guardian - UK

Treatment for finger-bending disease may be ‘gamechanger’

Clinical trial seems to show Dupuytren’s disease reversed by rheumatoid arthritis drug

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

The World's Largest Microdosing Clinical Trial Has Been Completed, Here Are The Results

Mindbio Therapeutics, a company of the Blackhawk Growth Corp. (OTCPK: BLRZF) announced the completion of the world’s largest Phase 1 clinical trial for LSD microdosing.

Benzinga

Why Kezar Life Sciences Shares Are Getting Hammered

Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading lower by 38.23% at $7.61 after the company announced top-line results from its PRESIDIO Phase 2 clinical trial of Zetomipzomib.

Benzinga

Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward

The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.

Benzinga

EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Reuters

Chinese Omicron-specific mRNA COVID vaccine candidate to be trialed in UAE

China's Suzhou Abogen Biosciences Co said its COVID-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates.

Benzinga

How To Enroll In A Psychedelic Clinical Trial In 5 Easy Steps

This article was originally published on Psychedelic Spotlight and appears here with permission. If you fail to meet even one of the inclusion criteria, or you meet even one of the exclusion criteria, then you are not eligible and you will not be selected for participation.

Benzinga

Pfizer, BioNTech Seeks Emergency Use Nod For COVID-19 Vaccine For Kids 5-11 Years

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have submitted an FDA Emergency Use Authorization (EUA) application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age. The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose…

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.